LOXL4 and cancer: In an orthotopic xenograft model (n = 4 and 5 for the control and LOXL4-knockdown groups, respectively), LOXL4 knockdown increased tumor volumes in the 5th and 6th weeks after cancer cell injection compared to the control (Figure 3A, P = 0.008 and P = 0.040, 5th and 6th weeks, respectively).